- Previous Close
0.2300 - Open
0.2300 - Bid 0.2200 x --
- Ask --
- Day's Range
0.2300 - 0.2300 - 52 Week Range
0.1850 - 0.4100 - Volume
500 - Avg. Volume
56,868 - Market Cap (intraday)
65.708M - Beta (5Y Monthly) 2.98
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments, Pharmaceuticals and Consumer Wellness. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream for epilepsy and pain management. The company is also involved in the development and sale of CBD-integrated pharmaceuticals and topical products. In addition, it develops and markets a portfolio of self-care products for healthier lifestyle. The company offers its products under the Innocan Pharma, R&G Relief & Go, Shir, Synony, and Add On trade names. InnoCan Pharma Corporation was incorporated in 2018 and is headquartered in Calgary, Canada.
innocanpharma.com--
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Drug Manufacturers - Specialty & Generic
Industry
Recent News: INNO.CN
View More
Performance Overview: INNO.CN
Trailing total returns as of 2024-11-01, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INNO.CN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INNO.CN
View MoreValuation Measures
Market Cap
65.71M
Enterprise Value
58.48M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.82
Price/Book (mrq)
9.79
Enterprise Value/Revenue
1.72
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-17.80%
Return on Assets (ttm)
-23.77%
Return on Equity (ttm)
-56.52%
Revenue (ttm)
24.39M
Net Income Avi to Common (ttm)
-4.34M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
5.19M
Total Debt/Equity (mrq)
0.07%
Levered Free Cash Flow (ttm)
1.3M